The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1551
ISSUE 1551
July 16, 2018
Issue 1551
- Lofexidine (Lucemyra) for Opioid Withdrawal
- Two New Drugs for Glaucoma
- Baricitinib (Olumiant) for Rheumatoid Arthritis
- Firvanq - Vancomycin Oral Solution
- Correction: Abuse-Deterrent Opioids
- Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)
- Apalutamide (Erleada) for Prostate Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Lofexidine (Lucemyra) for Opioid Withdrawal
July 16, 2018 (Issue: 1551)
The FDA has approved lofexidine (Lucemyra – US
WorldMeds/Salix), a centrally acting alpha2 receptor
agonist, to manage withdrawal symptoms in adults
abruptly stopping opioid use. Available in the UK since
1992, lofexidine is the first nonopioid...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.